Skip to main content Accessibility help
×
Hostname: page-component-77f85d65b8-pkds5 Total loading time: 0 Render date: 2026-04-12T15:35:22.005Z Has data issue: false hasContentIssue false

10 - Unipolar Depression and Its Treatment

Published online by Cambridge University Press:  22 July 2022

Stephen M. Stahl
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

A 26-year-old woman began treatment for a major depressive episode 8 months ago. Two months into her treatment she began to experience noticeable symptom improvement, and for the last 5 months she has been mostly symptom free, except for persistent cognitive dysfunction. Which of the following statements regarding cognitive dysfunction in depression is most accurate?

Information

Type
Chapter
Information
Stahl's Self-Assessment Examination in Psychiatry
Multiple Choice Questions for Clinicians
 , pp. 345 - 405
Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Pehrson, AL, Sanchez, C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr 2014;19(2):121–33.Google Scholar
Rock, PL, Roiser, JP, Riedel, WJ, Blackwell, AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med 2014;44(10):2029–40.Google Scholar
Zajecka, JM. Residual symptoms and relapse: mood, cognitive symptoms, and sleep disturbances. J Clin Psychiatry 2013;74(Suppl 2):9–13.Google Scholar
Zuckerman, H, Pan, Z, Park, C et al. Recognition and treatment of cognitive dysfunction in major depressive disorder. Front Psychiatry 2018;9:655.CrossRefGoogle ScholarPubMed

References

Ranjbar-Slamloo, Y, Fazlali, Z. Dopamine and noradrenaline in the brain; overlapping or dissociate functions? Front Mol Neurosci 2020;12:334.Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 7)Google Scholar

References

Enache, D, Pariante, CM, Mondelli, V. Markers of central inflammation in major depressive disorder: a systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. Brain Behav Immun 2019;81:24–40.CrossRefGoogle ScholarPubMed
Haapakoski, R, Mathieu, J, Ebmeier, KP, Alenius, H, Kivimäki, M. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun 2015;49:206–15.CrossRefGoogle ScholarPubMed
Köhler, CA, Freitas, TH, Maes, M et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand 2017;135(5):373–87.CrossRefGoogle ScholarPubMed
Raison, CL, Miller, AH. Is depression an inflammatory disorder? Curr Psychiatry Rep 2011;13:467–75.Google Scholar

References

Polyakova, M, Stuke, K, Schuemberg, K et al. BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis. J Affect Disord 2015;174:432–40.CrossRefGoogle ScholarPubMed
Sen, S, Duman, R, Sanacora, G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008;64(6):527–32.Google Scholar
Zhou, C, Zhong, J, Zou, B et al. Meta-analyses of comparative efficacy of antidepressant medications on peripheral BDNF concentration in patients with depression. PLoS One 2017;12(2):e0172270.Google Scholar

References

Serretti, A, Mandelli, L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010;71(10):1259–72.Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, the prescriber’s guide, seventh edition. New York, NY: Cambridge University Press; 2020.Google Scholar

Reference

Gillman, PK. A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths. J Neural Transm (Vienna) 2018;125(11):1707–17.Google Scholar

References

Dvir, Y, Smallwood, P. Serotonin syndrome: a complex but easily avoidable condition. Gen Hosp Psychiatry 2008;30(3):284–7.Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, the prescriber’s guide, seventh edition. New York, NY: Cambridge University Press; 2020.Google Scholar
Wimbiscus, M, Kostenkjo, O, Malone, D. MAO inhibitors: risks, benefits, and lore. Cleve Clin J Med 2010;77(12):859–82.Google Scholar

References

Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 7)Google Scholar
Thanacoody, HK, Thomas, SH. Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol Rev 2005;24(3):205–14.CrossRefGoogle ScholarPubMed

References

Stahl, SM. Stahl’s essential psychopharmacology, the prescriber’s guide, seventh edition. New York, NY: Cambridge University Press; 2020.CrossRefGoogle Scholar
Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 7)Google Scholar

References

Kennedy, SH, Rizvi, S. Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol 2009;29(2):157–64.Google Scholar
Serretti, A, Chiesa, A. Sexual side effects of pharmacological treatment of psychiatric diseases. Clin Pharmacol Ther 2011;89(1):142–7.Google Scholar

References

Artigas, F. Serotonin receptors involved in antidepressant effects. Pharmacol Ther 2013;137:119–31.Google Scholar
Carr, GV, Lucki, I. The role of serotonin receptor subtypes in treating depression: a review of animal studies. Psychopharmacology 2011;213:265–8.Google Scholar
Ciranna, L. Serotonin as a modulator of glutamate- and GABA-mediated neurotransmission: implications in physiological functions and in pathology. Curr Neuropharmacol 2006;4(2):101–14.Google Scholar
Pehrson, AL, Sanchez, C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr 2014;19(2):121–33.Google Scholar

References

Bech, P, Fava, M, Trivedi, MH, Wisniewski, SR, Rush, AJ. Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial. Acta Psychiatr Scand 2012;125(4):342–8.Google Scholar
Citrome, L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med 2010;122(4):39–48.Google Scholar
Trivedi, MH, Cutler, AJ, Richards, C et al. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram. J Clin Psychiatry 2013;74(8):802–9.Google Scholar
Zhou, X, Ravindran, AV, Qin, B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry 2015;76(4):e487–98.Google Scholar

References

Nutt, D, Demyttenaere, K, Janka, Z et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol 2007;21(5):461–71.CrossRefGoogle ScholarPubMed
Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 7)Google Scholar
Tomarken, AJ, Dichter, GS, Freid, C, Addington, S, Shelton, RC. Assessing the effects of bupropion SR on mood dimensions of depression. J Affect Disord 2004;78(3):235–41.Google Scholar

Reference

Sanacora, G, Frye, MA, McDonald, W et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry 2017;74(4):399–405.Google Scholar

References

Anttila, SA, Leinonen, EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001;7(3):249–64.Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapters 6, 7)CrossRefGoogle Scholar

References

Sarkisyan, G, Roberts, AJ, Hedlund, PB. The 5-HT7 receptor as a mediator and modulator of antidepressant-like behavior. Behav Brain Res 2010;209(1):99–108.Google Scholar
Stahl, SM. The serotonin-7 receptor as a novel therapeutic target. J Clin Psychiatry 2010;71(11):1414–15.Google Scholar

References

Sansone, RA, Sansone, LA. SSRI-induced indifference. Psychiatry (Edgemont) 2010;7(1):14–18.Google ScholarPubMed
Stahl, SM. Case studies: Stahl’s essential psychopharmacology. New York, NY: Cambridge University Press; 2011.Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, the prescriber’s guide, seventh edition. New York, NY: Cambridge University Press; 2017.Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 7)Google Scholar

References

Maguire, J. Neuroactive steroids and GABAergic involvement in the neuroendocrine dysfunction associated with major depressive disorder and postpartum depression. Front Cell Neurosci 2019;13:83.Google Scholar
Meltzer-Brody, S, Kanes, SJ. Allopregnanolone in postpartum depression: role in pathophysiology and treatment. Neurobiol Stress 2020;12:100212.Google Scholar
Pytka, K, Dziubina, A, Młyniec, K et al. The role of glutamatergic, GABA-ergic, and cholinergic receptors in depression and antidepressant-like effect. Pharmacol Rep 2016;68(2):443–50.Google Scholar

References

Anderson, KN, Lind, JN, Simeone, RM et al. Maternal use of specific antidepressant medications during early pregnancy and the risk of selected birth defects. JAMA Psychiatry 2020;77(12):1246–55.Google Scholar
Bérard, A, Sheehy, O, Zhao, JP et al. SSRI and SNRI use during pregnancy and the risk of persistent pulmonary hypertension of the newborn. Br J Clin Pharmacol 2017;83(5):1126–33.CrossRefGoogle ScholarPubMed
Biffi, A, Cantarutti, A, Rea, F et al. Use of antidepressants during pregnancy and neonatal outcomes: an umbrella review of meta-analyses of observational studies. J Psychiatr Res 2020;124:99–108.Google Scholar
Grigoriadis, S, Vonderporten, EH, Mamisashvili, L et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ 2014;348:f6932.Google Scholar
Sujan, AC, Rickert, ME, Öberg, AS et al. Associations of maternal antidepressant use during the first trimester of pregnancy with preterm birth, small for gestational age, autism spectrum disorder, and attention-deficit/hyperactivity disorder in offspring. JAMA 2017;317(15):1553–62.Google Scholar
Zhou, XH, Li, YJ, Ou, JJ, Li, YM. Association between maternal antidepressant use during pregnancy and autism spectrum disorder: an updated meta-analysis. Mol Autism 2018;9:21.Google Scholar

Reference

DeBodinat, C, Guardiola-Lemaitre, B, Mocaer, E et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization, and development. Nat Rev Drug Discov 2010;9:628–42.Google Scholar

References

Angst, J, Azorin, JM, Bowden, CL et al. Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode: the BRIDGE study. Arch Gen Psychiatry 2011;68(8):791–8.Google Scholar
Perlis, RH, Brown, E, Baker, RW, Nierenberg, AA. Clinical features of bipolar depression versus major depressive disorder in large multicenter trials. Am J Psychiatry 2006;163(2):225–31.Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 6)Google Scholar

References

Birmaher, B, Brent, D, AACAP Work Group on Quality Issues et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 2007;46(11):1503–26.Google Scholar
Dwyer, JB, Stringaris, A, Brent, DA, Bloch, MH. Annual research review: defining and treating pediatric treatment-resistant depression. J Child Psychol Psychiatry 2020;61(3):312–32.Google Scholar
Giles, LL, Martini, DR. Challenges and promises of pediatric psychopharmacology. Acad Pediatr 2016;16(6):508–18.Google Scholar
National Institute for Health and Care Excellence. Depression in children and young people: identification and management. NICE guideline [NG134]. 2019. Available at: www.nice.org.uk/guidance/ng134.Google Scholar
Walkup, JT. Antidepressant efficacy for depression in children and adolescents: industry- and NIMH-funded studies. Am J Psychiatry 2017;174(5):430–7.Google Scholar

References

Abdallah, CG, Adams, TG, Kelmendi, B, et al. Ketamine’s mechanism of action: a path to rapid-acting antidepressants. Depress Anxiety 2016;33(8):689–97.Google Scholar
Barbon, A, Caracciolo, L, Orlandi, C, et al. Chronic antidepressant treatments induce a time-dependent up-regulation of AMPA receptor subunit protein levels. Neurochem Int 2011;59(6):896–905.CrossRefGoogle ScholarPubMed
Bunney, BG, Bunney, WE. Rapid-acting antidepressant strategies: mechanisms of action. Int J Neuropsychopharmacol 2012;15(5):695–713.Google Scholar
Racagni, G, Popoli, M. Cellular and molecular mechanisms in the long-term action of antidepressants. Dialogues Clin Neurosci 2008;10(4):385–400.Google Scholar
Stahl, SM. Stahl’s Essential Psychopharmacology, fourth edition. New York, NY: Cambridge University Press; 2013. (Chapter 6)Google Scholar

Accessibility standard: Unknown

Why this information is here

This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.

Accessibility Information

Accessibility compliance for the HTML of this chapter is currently unknown and may be updated in the future.

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×